SOPHiA GENETICS (NASDAQ:SOPH) Insider Well Daan Van Sells 2,705 Shares

Key Points

• Insider sale: Well Daan Van sold 2,705 SOPH shares on April 6 at an average price of $4.86 under a pre-arranged Rule 10b5-1 plan to cover tax withholding, trimming his stake to 356,069 shares (≈$1.73M) — a 0.75% reduction.
• Broader insider activity: Multiple executives executed routine Rule 10b5-1 sales on April 6–7 totaling roughly 25,000 shares for about $120K at an average near $4.85–$4.88, with filings indicating these were plan-driven rather than opportunistic exits.
• Company and stock snapshot: SOPHiA GENETICS reported an EPS miss (‑$0.28 vs. ‑$0.20 expected) with revenue of $21.71M, trades near $4.86 (market cap ≈$333M), has negative margins/ROE, and carries an average analyst target of $7.00.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Well Daan Van sold 2,705 shares of SOPHiA GENETICS stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $4.86, for a total transaction of $13,146.30. Following the completion of the transaction, the insider directly owned 356,069 shares in the company, valued at approximately $1,730,495.34. The trade was a 0.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Well Daan Van also recently made the following trade(s):

• On Thursday, March 19th, Well Daan Van sold 684 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total transaction of $3,276.36.

SOPHiA GENETICS Stock Down 0.8%

SOPH traded down $0.04 during trading on Wednesday, hitting $4.86. The company had a trading volume of 71,758 shares, compared to its average volume of 188,492. The company has a market capitalization of $332.86 million, a PE ratio of -9.53 and a beta of 1.04. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. SOPHiA GENETICS SA has a one year low of $2.58 and a one year high of $5.70. The firm's 50-day moving average price is $4.78 and its 200 day moving average price is $4.68.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). The firm had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. As a group, equities analysts expect that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Neutral Sentiment: Multiple insiders executed pre-arranged Rule 10b5-1 sales to cover tax obligations — CEO Jurgi Camblong, President Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma, and others. Collectively ~25,000 shares were sold over April 6–7 for roughly $120k at an average price near $4.85–$4.88. Executives still retain large positions, and filings note these were routine plan-driven sales rather than opportunistic exits. CEO Form 4 President Form 4 Insider Form 4

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. BTIG Research reiterated a "buy" rating and issued a $7.00 price objective on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Finally, Guggenheim increased their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $7.00.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of institutional investors have recently added to or reduced their stakes in SOPH. Savvy Advisors Inc. acquired a new stake in SOPHiA GENETICS in the third quarter valued at $48,000. Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS in the 3rd quarter valued at about $49,000. Perkins Capital Management Inc. bought a new position in SOPHiA GENETICS during the fourth quarter worth about $49,000. Quadrature Capital Ltd bought a new position in SOPHiA GENETICS during the fourth quarter worth about $54,000. Finally, XTX Topco Ltd acquired a new position in SOPHiA GENETICS during the fourth quarter worth approximately $55,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.